ATE412412T1 - Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs - Google Patents

Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs

Info

Publication number
ATE412412T1
ATE412412T1 AT03792487T AT03792487T ATE412412T1 AT E412412 T1 ATE412412 T1 AT E412412T1 AT 03792487 T AT03792487 T AT 03792487T AT 03792487 T AT03792487 T AT 03792487T AT E412412 T1 ATE412412 T1 AT E412412T1
Authority
AT
Austria
Prior art keywords
cyclyl
gnrh
alkylaminoalkyl
pyrazole
antagonists
Prior art date
Application number
AT03792487T
Other languages
English (en)
Inventor
Thomas Bird
Matthias Herdemann
Mickael Maudet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE412412T1 publication Critical patent/ATE412412T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
AT03792487T 2002-08-21 2003-08-19 Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs ATE412412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02292077 2002-08-21

Publications (1)

Publication Number Publication Date
ATE412412T1 true ATE412412T1 (de) 2008-11-15

Family

ID=31896982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792487T ATE412412T1 (de) 2002-08-21 2003-08-19 Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs

Country Status (10)

Country Link
US (1) US7514570B2 (de)
EP (1) EP1531811B1 (de)
JP (1) JP2006505528A (de)
AR (1) AR041030A1 (de)
AT (1) ATE412412T1 (de)
AU (1) AU2003255820A1 (de)
DE (1) DE60324431D1 (de)
ES (1) ES2314277T3 (de)
TW (1) TW200413351A (de)
WO (1) WO2004017961A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942190A (zh) * 2004-02-20 2007-04-04 阿斯利康(瑞典)有限公司 用作促性腺激素释放激素(GnRH)拮抗剂的吡咯衍生物
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
DK1781618T3 (da) 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
AU2005276590B2 (en) 2004-08-27 2011-05-19 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829875A1 (de) 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazolderivate als Inhibitoren des Sigma-Rezeptors
EP1829866A1 (de) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Inhibitoren von Sigmarezeptoren
EP1829867A1 (de) 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Gegenüber dem Sigmarezeptor pharmazeutisch aktive Imidazolverbindungen
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2353598A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
EP2395003A1 (de) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazolverbindungen als Sigmarezeptor-Inhibitoren
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP3082782A1 (de) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Kombinationen aus serotonin-norepinephrin-wiederaufnahmehemmern (snris) und sigma-rezeptorliganden
CN104557711B (zh) * 2014-12-26 2017-12-15 南通大学 含fts结构的吡唑肟类化合物的制备和应用
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1997021707A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1997021704A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
SK77598A3 (en) 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use
JP3092947B2 (ja) 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
JPH10287655A (ja) * 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7806998A (en) 1997-06-05 1998-12-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1998055470A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0986385A4 (de) 1997-06-05 2001-05-16 Merck & Co Inc Antagonisten des gonadorelins
US6156772A (en) 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU729663B2 (en) 1997-06-05 2001-02-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU728811B2 (en) 1997-06-05 2001-01-18 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2308454A1 (en) 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU1197299A (en) 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002503661A (ja) 1998-02-11 2002-02-05 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
EP1068195A1 (de) 1998-02-11 2001-01-17 Merck & Co., Inc. Antagonisten des "gonadotropin releasing hormone"
JP2002510630A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
EP1067930A4 (de) 1998-04-02 2002-09-18 Merck & Co Inc Antagonisten des gonadoliberins
AU3368299A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051595A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051596A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2325995A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69915862T2 (de) * 1998-11-20 2004-08-05 G.D. Searle Llc Verfahren zur herstellung 5-substituierter pyrazole unter verwendung von dithietane
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
JP2002539124A (ja) 1999-03-10 2002-11-19 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物
JP2002538205A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物
WO2000053181A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2367116A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3868800A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US6583153B2 (en) * 2000-12-12 2003-06-24 Ortho-Mcneil Pharmaceutical, Inc. 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
MXPA04005999A (es) 2001-12-21 2005-07-13 Taisho Pharma Co Ltd Derivado de piperazina.

Also Published As

Publication number Publication date
JP2006505528A (ja) 2006-02-16
EP1531811B1 (de) 2008-10-29
WO2004017961A2 (en) 2004-03-04
AU2003255820A1 (en) 2004-03-11
AR041030A1 (es) 2005-04-27
US20060287379A1 (en) 2006-12-21
ES2314277T3 (es) 2009-03-16
AU2003255820A8 (en) 2004-03-11
EP1531811A2 (de) 2005-05-25
DE60324431D1 (de) 2008-12-11
US7514570B2 (en) 2009-04-07
TW200413351A (en) 2004-08-01
WO2004017961A3 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE412412T1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
IL169897A0 (en) Sustituted heterocycles
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
SI1556058T1 (sl) Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
TW200612918A (en) Lonidamine analogs
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
BG66080B1 (bg) Заместени тиоацетамиди
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
MY137766A (en) Exemestane as chemopreventing agent
ATE355288T1 (de) Verbindungen und therapeutische methoden
IS2869B (is) Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE369147T1 (de) Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen
MD3222G2 (ro) Metodă de diagnostic al cancerului endometrial
DE602006018619D1 (de) Zusammensetzungen zur behandlung von luminalen entzündlichen erkrankungen
MD2872G2 (ro) Metodă de pronostic al riscului apariţiei hiperplaziei dishormonale a glandei mamare
TW200605891A (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties